Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Clean hands are a must, so wash them thoroughly before you start
Im not quite getting it just yet
The candidate previously demonstrated promising weight loss outcomes in Phase 2 trials, and its progression into late-stage testing underscores the competitive momentum building in this high-growth therapeutic category In January 2024, Zealand Pharma and Boehringer Ingelheim announced positive Phase 2 results for BI 456906, a long-acting GLP-1/glucagon dual agonist, in obese individuals
Its cyclic structure gives it better stability than linear -MSH, making it one of the most widely used compounds in melanocortin receptor research
US$ 20.03
US$ 22.45
US$ 27.63
US$ 22.52
